News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Studies Highlight The Potential Of Liraglutide, Novo Nordisk’s Investigational GLP-1 Analogue
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Long-Acting Analogue Offers Improved Blood Glucose Control, Weight Control and Low Risk of Hypoglycaemia, in a Once-Daily Treatment
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Novo Nordisk
MORE ON THIS TOPIC
Stomach cancer
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
January 7, 2026
·
2 min read
·
Tristan Manalac
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
January 7, 2026
·
2 min read
·
Heather McKenzie
Insights
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
January 7, 2026
·
3 min read
·
Jennifer Smith-Parker
Weight Loss
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
January 6, 2026
·
3 min read
·
Annalee Armstrong
